20 August 2019
The worldwide trade of the cephalosporin class of antibiotics will increase to $14.1 billion by the end of 2025.
The global cephalosporin drugs market is expected to increase at a compound annual growth rate (CAGR) of 3.34 percent in the forecast period to 2025, according to a report.
The trade of the semi-synthetic, wide-spectrum antibiotics is predicted to reach $14.1 billion by the end of the forecast period.
The research, conducted by Reportlinker, suggests that increasing incidences of pneumonia, tonsillitis, bronchitis and gonorrhoea are the main variables contributing to market growth.
Increasing R&D operations to create extremely effective and secure medicines as well as increasing the use of combination therapies further enhance the growth of the market.
However, the growth is reportedly restricted due to the side effects of cephalosporin drugs and the development of drug-resistant bacterial strains.
Key players in the industry include Bayer AG, Teva Pharmaceuticals and GlaxoSmithKline (GSK).
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024